

InnoCan Pharma

08:15 22 May 2020

InnoCan Pharma inks agreement with ADVA to produce exosomes for its CBD-loaded treatments

InnoCan Pharma Corporation (CSE:INNO) said Friday that its wholly-owned subsidiary, InnoCan Pharma Ltd, has signed a letter of intent with ADVA Biotechnology Ltd to develop and produce exosomes for use in its CBD-loaded exosome (CLX) treatments.

In layman's terms, exosomes are extracellular vesicles, crucial in cell-to-cell communication which are being explored as a means of drug delivery.

The letter of intent outlines the terms of an exosome production and development agreement which both companies intend to negotiate and conclude within 120 days from May 21. ADVA is an Israeli company that specializes in the development of end-to-end advanced therapy manufacturing solutions.

READ: InnoCan Pharma appoints Professor Daniel Offen as scientific advisor following Tel Aviv University deal

The exosome production agreement will provide a framework for the production of exosomes and related development services by ADVA.

As part of Innocan's research activities with the Tel Aviv University led by Professor Daniel Offen, Innocan intends to load the produced exosomes with CBD in its efforts to develop a treatment for coronavirus (COVID-19) and additional central nervous system disorders.

ADVA will provide its services in three crucial stages:

- Stage 1: Pilot study involving the production of exosomes from 4 to 6 production runs according to Innocan's specifications, expected to be completed in 6 to 8 weeks
- Stage 2: Production of exosomes from 4 to 5 different donors, conducting comparable tests, production process optimization and characterization of the final exosome product
- Stage 3: Upscaling the finalized exosome product for commercial production

As part of the deal, Innocan will make certain payments to ADVA within five days of signing of the letter of intent and upon the successful completion of Stage 1.

In a statement, Innocan CEO Iris Bincovich said the company is "looking forward" to working with the ADVA team which brings "experience of many years in development of bioreactors" at the "highest level of mesenchymal stem cell production."

"The uniqueness of the mesenchymal stem cell production unit to be developed by ADVA under the LOI and the Exosome Production Agreement is expected to provide Innocan with full control of many important parameters of the exosome production process, allowing Innocan and Professor Offen's team to optimize the exosome and production

Price: 0.3

Market Cap: \$52.6 m

1 Year Share Price Graph



Share Information

Code: INNO

Listing: CSE

52 week High Low
0.35 0.05

Sector: Cannabis

Website: innocanpharma.com

Company Synopsis:

Innocan Pharma™ combines pharmaceutical experience with technological innovation to deliver the new generation of CBD integrated pharma and cosmetics products.

action@proactiveinvestors.com

system," Bincovich added.

ADVA founder CEO Ohad Karnieli said: "We are very pleased to collaborate with Innocan and Professor Offen's team on the CLX project."

He added: "Our technology is an excellent fit to Innocan's needs and the ability of having full control and high flexibility at the production process may lead to better, faster and high yield production of the exosomes and cells."

ADVA has developed an automated, controlled and simple to use platform for cell manufacturing.

InnoCan is a specialty pharmaceutical company that develops products that harness the unique properties of cannabinoids combined with smart delivery formulations. Innocan and Tel Aviv University are collaborating on developing a new exosome-based technology that targets both central nervous system disorders and the coronavirus.

Last month, Innocan revealed that CBD-loaded Exosomes hold the potential to provide anti-inflammatory properties and help infected lung cells to recover. The company's product, which is expected to be administered by inhalation, will be tested against a variety of lung infections.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).